Bolt Biotherapeutics (BOLT)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	11.14 mm	11.14 mm	11.14 mm	11.14 mm	11.14 mm	11.14 mm
Cash burn (monthly)	(no burn)	(no burn)	5.48 mm	6.32 mm	4.66 mm	5.09 mm
Cash used (since last report)	n/a	n/a	23.34 mm	26.94 mm	19.83 mm	21.69 mm
Cash remaining	n/a	n/a	-12.20 mm	-15.80 mm	-8.69 mm	-10.55 mm
Runway (months of cash)	n/a	n/a	-2.2	-2.5	-1.9	-2.1

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

BOLT institutional ownership history Ownership history

79.2% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	36	41	-12.2%
Opened positions	2	4	-50.0%
Closed positions	7	6	+16.7%
Increased positions	8	13	-38.5%
Reduced positions	8	6	+33.3%

13F shares	Current	Prev Q	Change
Total value	12.18 bn	16.98 bn	-28.3%
Total shares	30.32 mm	34.16 mm	-11.3%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Tang Capital Management	3.81 mm	$2.47 bn	0.0%
Tang Capital Partners	3.65 mm	$3.91 mm	0.0%
Vivo Capital	3.52 mm	$2.28 bn	0.0%
Pivotal bioVenture Partners Fund I	3.06 mm	$3.30 mm	0.0%
Sofinnova Investments	2.75 mm	$1.78 bn	0.0%
Sofinnova Venture Partners X	2.75 mm	$0.00	0.0%
Vivo Capital VIII	2.07 mm	$2.22 mm	0.0%
Pivotal bioVenture Partners Investment Advisor	1.89 mm	$1.23 bn	0.0%
Nan Fung	1.17 mm	$756.19 mm	0.0%
Vanguard	1.07 mm	$691.68 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
Citadel Advisors	0.00	-2.37 mm	EXIT
Newtyn Management	468.91 k	-894.32 k	-65.6%
Acuitas Investments	0.00	-630.51 k	EXIT
BlackRock	269.61 k	+269.61 k	NEW
BLK BlackRock	0.00	-267.07 k	EXIT
Susquehanna International	147.93 k	+125.52 k	+560.1%
Marquette Asset Management	0.00	-113.80 k	EXIT
ADAR1 Capital Management	244.97 k	+58.97 k	+31.7%
Mariner	40.53 k	+40.53 k	NEW
FMR	115.39 k	+28.77 k	+33.2%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

BOLT insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
3 Sep 24	Dupont Jakob	Stock Option Common Stock	Grant	Acquire A	No	No	0.6798	16,984	11.55 k	16,984
3 Sep 24	Dupont Jakob	Stock Option Common Stock	Grant	Acquire A	No	No	0.6798	50,000	33.99 k	50,000
23 Jul 24	Sarah Nemec	Stock Option Common Stock	Grant	Acquire A	No	No	0.7301	90,000	65.71 k	90,000
23 Jul 24	Sarah Nemec	Stock Option Common Stock	Grant	Acquire A	No	No	0.7301	50,000	36.51 k	50,000
23 Jul 24	Quinn William P.	Stock Option Common Stock	Grant	Acquire A	No	No	0.7301	440,000	321.24 k	440,000
23 Jul 24	Grant Yonehiro	Stock Option Common Stock	Grant	Acquire A	No	No	0.7301	155,000	113.17 k	155,000

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

HC Wainwright & Co. Reiterates Neutral on Bolt Biotherapeutics

13 Nov 24

HC Wainwright & Co. analyst Edward White reiterates Bolt Biotherapeutics (NASDAQ:BOLT) with a Neutral.

Bolt Biotherapeutics Q3 2024 GAAP EPS $(0.40) Misses $(0.35) Estimate, Sales $1.141M Miss $1.263M Estimate

12 Nov 24

Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.35) by 14.29 percent. The company reported quarterly sales of $1.141 million which